Valneva’s Brazil Production Go-Ahead Provides a Rare Bright Spot Amid Deepening Quarterly Losses

Valneva has secured a crucial operational win in Latin America just as its first-quarter results reveal a sharp deterioration in its finances. Brazil’s health regulator ANVISA on May 4 authorised the Instituto Butantan to locally manufacture the Chikungunya vaccine IXCHIQ, a move that brings the shot closer to widespread use in the country’s public health system.

The authorisation is more than a routine approval. Until now, all IXCHIQ doses shipped to Brazil had to be produced at Valneva’s foreign facilities. Local formulation and packaging will allow Butantan to supply the vaccine directly, supporting a broader rollout under Brazil’s Sistema Único de Saúde (SUS). Valneva and Butantan have already pledged up to 500,000 doses to the health ministry.

A pilot SUS programme has been running since February, targeting communities with high disease burdens. So far more than 23,000 people have received a dose. The need is stark: Brazil recorded over 127,000 Chikungunya cases and 125 deaths last year, while the global tally hit roughly 620,000 infections.

The Brazilian progress is a welcome counterweight to the company’s struggles in the United States. Valneva voluntarily withdrew its US application for IXCHIQ in January 2026, after the FDA suspended the licence the previous August. The shot is approved in Europe and Canada for people aged 12 and above, and in the UK and Brazil for adults aged 18 to 59.

Should investors sell immediately? Or is it worth buying Valneva?

Against this mixed pipeline backdrop, the first-quarter numbers landed heavily. Valneva reported a net loss of €32.1 million for the three months to March 2026, more than triple the €9.2 million loss in the same period last year. One-off write-downs and contract terminations battered the bottom line, while sales of travel vaccines slumped.

Revenue from the Japanese encephalitis vaccine Ixiaro fell to €20.2 million, which Valneva attributed to delayed shipments to the US military. Dukoral, the cholera vaccine, brought in just €8.6 million. A planned exit from distributing third-party products further weighed on revenue.

Management wasted no time in responding. The company is cutting up to 15% of its global workforce as part of a harsh cost-saving programme. The full-year revenue guidance has been trimmed to a range of €145 million to €160 million, down from previous expectations. Chief Financial Officer Peter Bühler cited geopolitical tensions as a drag on travel vaccine demand.

The stock has already priced in much of the pain. On the day of the Q1 release, shares edged up 1.1% to €2.59, but that comes after a roughly 33% decline since the start of 2026. The 52-week high of €5.16 looks distant.

Valneva at a turning point? This analysis reveals what investors need to know now.

Investors are still pinning their hopes on the late-stage pipeline. The Lyme disease vaccine candidate, developed with Pfizer, posted a 73.2% reduction in confirmed Lyme cases from 28 days after the fourth dose in the Phase 3 VALOR trial. The study accrued fewer events than expected, and the first analysis missed the pre-specified statistical endpoint, but a second evaluation met the bar. Pfizer has described the efficacy as clinically relevant and plans to file for regulatory approval in the US and Europe during the second half of 2026.

That filing window is the most significant catalyst on Valneva’s horizon. The current Brazil authorisation and the cost cuts buy time, but the real valuation lever remains the Lyme programme and whether Pfizer’s late-2026 submission can turn the narrative around.

Ad

Valneva Stock: New Analysis - 13 May

Fresh Valneva information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Valneva analysis...

en | FR0004056851 | VALNEVA’S | boerse | 69323885 |